& x20;Which of the following statements is correct regarding Ticagrelor? - INI-CET EXAM -2026

INI-CET EXAM -2026

Pharmacology

Easy

Appeared in: INI-CET EXAM -2026

Explanation

Ticagrelor is an antiplatelet medication used to prevent thrombotic events, particularly in patients with acute coronary syndrome (ACS).
Its mechanism of action involves directly blocking the P2Y12 receptor on the surface of platelets.
This blockade prevents adenosine diphosphate (ADP) from binding to the receptor, which in turn inhibits platelet activation and aggregation.
Unlike some other P2Y12 inhibitors, Ticagrelor's binding is direct and reversible, and it does not require metabolic activation to be effective.

Option A: This statement is false. Clinical trials have not shown a reduced risk of intracranial bleeding with ticagrelor compared to clopidogrel. While ticagrelor is more potent, it is associated with a higher risk of non-CABG-related major bleeding, and the risk of intracranial hemorrhage is similar.
Option B: This describes the pharmacokinetics of thienopyridines like clopidogrel and prasugrel, which are prodrugs. Ticagrelor is administered in its active form and does not require hepatic activation.
Option D: This describes the action of clopidogrel, which binds irreversibly to the P2Y12 receptor for the life of the platelet. Ticagrelor's binding is reversible, allowing for a faster offset of its antiplatelet effect (3-5 days) after the drug is stopped.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Pharmacology of Antiplatelet Agents: Ticagrelor as background academic context rather than a clinical decision trigger.
Understanding the differences between P2Y12 inhibitors is crucial for nurses managing patients with ACS. The choice of agent impacts bleeding risk, need for genetic testing (for clopidogrel), and management before surgery.
A key nursing responsibility is monitoring for signs of bleeding (e.g., bruising, hematuria, melena) and educating the patient on these risks. For ticagrelor, nurses should also be aware of the potential side effect of dyspnea.
The reversible action of ticagrelor is a major advantage for patients who may require urgent surgery, such as CABG. It allows for a shorter discontinuation period (e.g., 3-5 days) compared to clopidogrel (5-7 days), reducing surgical delays and associated risks.

How to Approach the Question

First, identify the drug in the question stem: Ticagrelor. Recognize it as a P2Y12 inhibitor, a class of antiplatelet agents.
Recall the key pharmacological properties of Ticagrelor: its class (not a thienopyridine), mechanism (direct P2Y12 inhibition), activation (not a prodrug), and binding characteristics (reversible).
Evaluate each option against these known properties.
Option A deals with a clinical outcome (bleeding risk). Recall or deduce that more potent antiplatelets generally carry a higher, not lower, bleeding risk. The claim of 'reduced' risk is a red flag.
Option B tests knowledge of pharmacokinetics (activation). Remember that Ticagrelor is direct-acting, unlike Clopidogrel, which is a prodrug.
Option C describes the core mechanism of action. This aligns with the known pharmacology of Ticagrelor.

Concept Tested & Keywords

Qe84itQSNWlB4GRWqDvkFG

E6 Medicine Harrison 22e Part 1 p. 985-987

E6 Pharmacology Katzung 16e p. 968-970